Citations

Showing 10 of 108119 citations.

Usefulness of a Longitudinal Fixing Method with Two Bulldog Vascular Clamps for End-to-Side Anastomosis in Head and Neck Reconstruction
Shin, Jin Yong , Roh, Si‐Gyun , Chang, Suk Choo , Lee, Nae‐Ho

Mayo Clinic

Plastic & Reconstructive Surgery | February 28, 2019 | Volume: 143 | Issue: 3 | Pages: 675e-677e

10.1097/prs.0000000000005358 | PMID 30601317 Get It

Meaningful Use of Social Media for Prospective Plastic Surgery Residency Candidates
Restrepo, David J. , Rinker, Brian, Forte, Antonio J. , Boczar, Daniel , Forte, Antonio Jorge , Sisti, Andrea

Mayo Clinic

Plastic & Reconstructive Surgery | February 28, 2019 | Volume: 143 | Issue: 3 | Pages: 670e-671e

10.1097/prs.0000000000005349 | PMID 30601307 Get It

Evaluation of the In Vivo Kinetics and Biostimulatory Effects of Subcutaneously Injected Hyaluronic Acid Filler
Restrepo, David J. , Forte, Antonio J. , Sisti, Andrea , Boczar, Daniel , Forte, Antonio Jorge , Nisi, Giuseppe

Mayo Clinic

Plastic & Reconstructive Surgery | February 28, 2019 | Volume: 143 | Issue: 3 | Pages: 659e-659e

10.1097/prs.0000000000005332 | PMID 30601297 Get It

A Systematic Review for Variables to Be Collected in a Transplant Database for Improving Risk Prediction
Almasri, Jehad , Tello, Mouaffaa, Benkhadra, Raed, Morrow, Allison S. , Farah, Wigdan , Álvarez‐Villalobos, Neri Alejandro , Mohammed, Khaled , Allen, Jay-Sheree , Kasiske, Bertram L. , Murad, M. Hassan , Hasan, Bashar , Alvarez Villalobos, Neri, Allen, Jay-Sheree P, Murad, Mohammad Hassan, Murad, M Hassan , Álvarez-Villalobos, Neri A , Hasan, Bashar , Prokop, Larry J. , Wang, Zhen , Israni, Ajay K. , Farah, Wigdan

Mayo Clinic

Transplantation | February 28, 2019 | Volume: 103 | Issue: 12 | Pages: 2591-2601

10.1097/tp.0000000000002652 | PMID 30768569 Get It

Background. This systematic review was commissioned to identify new variables associated with transplant outcomes that are not currently collected by the Organ Procurement and Transplantation Network (OPTN). Methods. We identified 81 unique studies including 1 193 410 patients with median follow-up of 36 months posttransplant, reporting 108 unique risk factors. Results. Most risk factors (104) were recipient related; few (4) were donor related. Most risk factors were judged to be practical and feasible to routinely collect. Relative association measures were small to moderate for most risk factors (ranging between 1.0 and 2.0). The strongest relative association measure for a heart transplant outcome with a risk factor was 8.6 (recipient with the previous Fontan operation), for a kidney transplant 2.8 (sickle cell nephropathy as primary cause of end-stage renal disease), for a liver transplant 14.3 (recipient serum ferritin >500 µg/L), and for a lung transplant 6.3 (Burkholderia cepacia complex infection for 1 y or less). OPTN may consider some of these 108 variables for future collection to enhance transplant research and clinical care. Conclusions. Evidence-based approaches can be used to determine variables collected in databases and registries. Several candidate variables have been identified for OPTN.
Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post–kidney Transplantation: A Consecutive Series of 15 Cases
Tan, Ek Khoon , Bentall, Andrew , Dean, Patrick G. , Shaheen, Mohammed F. , Stegall, Mark D. , Stegall, Mark D , Bentall, Andrew , Schinstock, Carrie A.

Mayo Clinic

Transplantation | February 28, 2019 | Volume: 103 | Issue: 11 | Pages: 2397-2404

10.1097/tp.0000000000002639 | PMID 30801549 Get It

Background. Active antibody-mediated rejection (AMR) that occurs during the amnestic response within the first month posttransplant is a rare but devastating cause of early allograft loss after kidney transplant. Prior reports of eculizumab treatment for AMR have been in heterogeneous patient groups needing salvage therapy or presenting at varied time points. We investigated the role of eculizumab as primary therapy for active AMR early posttransplant. Methods. We performed a retrospective observational study of a consecutive cohort of solitary kidney transplant recipients who were transplanted between January 1, 2014, and January 31, 2018, and had AMR within the first 30 days posttransplant and treated with eculizumab ± plasmapheresis. Results. Fifteen patients had early active AMR at a median (interquartile range [IQR]) of 10 (7–11) days posttransplant and were treated with eculizumab ± plasmapheresis. Thirteen cases were biopsy proven, and 2 cases were presumed on the basis of donor-specific antibody trends and allograft function. Within 1 week of treatment, the median estimated glomerular filtration rate increased from 21 to 34 mL/min (P = 0.001); and persistent active AMR was only found in 16.7% (2/12) of biopsied patients within 4–6 months. No graft losses occurred, and at last follow-up (median [IQR] of 13 [12–19] mo), the median IQR estimated glomerular filtration rate increased to 52 (46–60) mL/min. Conclusions. Prompt eculizumab treatment as primary therapy is safe and effective for early active AMR after kidney transplant or abrupt increases in donor-specific antibodies when biopsy cannot be performed for diagnosis confirmation.
Noncontrast Chest Computed Tomographic Imaging of Obesity and the Metabolic Syndrome
Schlett, Christopher L. , Nattenmüller, Johanna , Tsuchiya, Nanae , Vogel‐Claussen, Jens , Kauczor, Hans‐Ulrich , Levin, David L. , Hatabu, Hiroto , Estépar, Jose R., Wu, Ming-Ting , Levin, David, Beek, Edwin J.R. van , Schiebler, Mark , Vogel-Claussen, Jens

Mayo Clinic

Journal of Thoracic Imaging | February 28, 2019 | Volume: 34 | Issue: 2 | Pages: 116-125

10.1097/rti.0000000000000391 | PMID 30802234 Get It

There are physiological consequences of overeating that can lead to increased morbidity and mortality. The purpose of this review article is to acquaint the reader with the current state of the art in the non–cardiac-gated, noncontrast chest computed tomographic (NCCT) imaging biomarkers of the metabolic syndrome and their prognostic significance found in the lower neck and chest. NCCT imaging biomarkers associated with metabolic syndrome in the chest include premature coronary artery calcification, acceleration of large vessel arterial and valvular calcifications associated with atherosclerosis, and pulmonary arterial enlargement from pulmonary hypertension associated with sleep apnea. These easily identified imaging biomarkers have prognostic implications for major adverse cardiac events (MACE). These NCCT chest-imaging biomarkers are likely targets for artificial intelligence algorithms to harvest for longitudinal assessment of their individual and multifactorial contributions to chronic disease, MACE, and mortality. Early recognition and treatment of these common disorders may help improve patient outcomes and quality of life while decreasing medical costs.
What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas, Abbie S., Porter, Alyx B. , Sharma, Akanksha , Knox, Molly, Marks, Lisa , Wingerchuk, Dean M. , O’Carroll, Cumara B. , Marks, Lisa A., Marks, Lisa A , Ornelas, Abbie S.

Mayo Clinic

The Neurologist | February 28, 2019 | Volume: 24 | Issue: 2 | Pages: 71-73

10.1097/nrl.0000000000000222 | PMID 30817495 Get It

Alternating electrical fields can disrupt mitosis leading to apoptosis of rapidly dividing cancer cells. The device that utilizes this mechanism is known as tumor-treating fields (TTFields). TTFields can be applied by ceramic transducer arrays on a shaved scalp to deliver the alternating electric activity to patients with glioblastoma (GBM). It has FDA approval for use in both recurrent and newly diagnosed GBM. The objective is to critically appraise the current evidence for the use of TTFields as adjunctive treatment to newly diagnosed GBM. The objective was addressed through the development of a structured, critically appraised topic. We incorporated a clinical scenario, background information, a structured question, literature search strategy, evidence summary, clinical bottom lines, and expert discussion. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of neurooncology. A randomized controlled trial was selected for critical appraisal. Patients with newly diagnosed GBM completing standard radiation and chemotherapy with temozolomide (TMZ) were subsequently randomized to receive maintenance TMZ with TTFields, or TMZ alone. With the addition of TTFields, median progression-free survival was 6.7 months compared with 4 months without the addition of TTFields (95% confidence interval, 0.52-0.76; P<0.001) and overall survival was 20.9 months compared with 16.0 months without the addition of TTFields (95% confidence interval, 0.53-0.76; P<0.001). TTFields may increase both progression-free and overall survival in patients receiving standard chemoradiation therapy for GBM.
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramanathan, Ramesh K., McDonough, Shannon, Hingorani, Sunil R. , Lacy, Jill , Kortmansky, Jeremy , Thumar, Jaykumar , Chiorean, E. Gabriela , Shields, Anthony F. , Behl, Deepti , Mehan, Paul, Gaur, Rakesh , Seery, Tara Elisabeth , Guthrie, Katherine A. , Höchster, Howard S. , Philip, Philip A.

Mayo Clinic

Journal of Clinical Oncology | February 28, 2019 | Volume: 37 | Issue: 13 | Pages: 1062-1069

10.1200/jco.18.01295 | PMID 30817250 Get It

PURPOSE Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated in patients with metastatic pancreatic cancer (mPC). MATERIALS AND METHODS Patients had untreated mPC, a performance status of 0 to 1, and adequate organ function. Tumor HA status was not required for eligibility. After a phase Ib dose-finding study of mFOLFIRINOX plus PEGPH20, the phase II open-label study randomly assigned patients (1:1) to the combination arm or to mFOLFIRINOX alone (n = 138). The primary end point was overall survival (OS). RESULTS PEGPH20 dosages of 3 µg/kg every 2 weeks were more tolerable than twice-weekly dosages used in the phase I study, so 3 µg/kg every 2 weeks was the phase II dosage. An amendment instituted enoxaparin prophylaxis in the PEGPH20 combination arm as a result of increased thromboembolic (TE) events. The planned interim futility analysis when 35 deaths (of 103 analyzable patients) occurred resulted in an OS hazard ratio (HR) of 2.07 that favored the control arm, and the study was closed to accrual. The treatment-related grade 3 to 4 toxicity was significantly increased in the PEGPH20 combination arm relative to control (odds ratio, 2.7; 95% CI, 1.1 to 7.1). The median OS in the mFOLFIRINOX arm was 14.4 months (95% CI, 10.1 to 15.7 months) versus 7.7 months (95% CI, 4.6 to 9.3 months) in the PEGPH20 combination arm. CONCLUSION Addition of PEGPH20 to mFOLFIRINOX seems to be detrimental in patients unselected for tumor HA status. This combination caused increased toxicity (mostly GI and TE events) and resulted in decreased treatment duration compared with mFOLFIRINOX alone. The median OS in the mFOLFIRINOX control arm (14.4 months) is, to our knowledge, the longest yet reported and can be considered for patients with good PS.
The “Skinny” on Assessment and Utilization of Steatotic Liver Grafts: A Systematic Review
Croome, Kristopher P. , Lee, David D. , Taner, C. Burcin , Croome, Kris P , Lee, David D

Mayo Clinic

Liver Transplantation | February 28, 2019 | Volume: 25 | Issue: 3 | Pages: 488-499

10.1002/lt.25408 | PMID 30817859 Get It

The frequency at which steatotic deceased donor liver grafts are encountered will likely continue to increase. Utilization of liver grafts with moderate‐to‐severe steatosis for liver transplantation (LT) has been previously shown to be associated with increased rates of primary nonfunction and decreased recipient survival. In order to better inform clinical decision making and guide future research, critical evaluation of the literature on donor liver steatosis and posttransplantation outcome is needed. This literature review aims to provide the “skinny” on using deceased donor steatotic livers for LT.
Melatonin Enhances Cisplatin and Radiation Cytotoxicity in Head and Neck Squamous Cell Carcinoma by Stimulating Mitochondrial ROS Generation, Apoptosis, and Autophagy
Fernández-Gil, Beatriz I. , Guerra‐Librero, Ana , Shen, Yingqiang , Florido, Javier , Martínez-Ruiz, Laura , García‐López, Sergio, Adan, Christian, Rodríguez-Santana, César , Acuña-Castroviejo, Darı́o , Quiñones‐Hinojosa, Alfredo , Moneim, Ahmed E. Abdel , Ferrer, José M. Rodríguez, Escames, Germaine , Abdel Moneim, Ahmed E , Escames, Germaine , García-López, Sergio, Fernández‐Martínez, José , López, Luis Carlos

Mayo Clinic

Oxidative Medicine and Cellular Longevity | February 28, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-12

10.1155/2019/7187128 | PMID 30944696 Get It

Head and neck cancer is the sixth leading cancer by incidence worldwide. Unfortunately, drug resistance and relapse are the principal limitations of clinical oncology for many patients, and the failure of conventional treatments is an extremely demoralizing experience. It is therefore crucial to find new therapeutic targets and drugs to enhance the cytotoxic effects of conventional treatments without potentiating or offsetting the adverse effects. Melatonin has oncostatic effects, although the mechanisms involved and doses required remain unclear. The purpose of this study is to determine the precise underlying mitochondrial mechanisms of melatonin, which increase the cytotoxicity of oncological treatments, and also to propose new melatonin treatments in order to alleviate and reverse radio- and chemoresistant processes. We analyzed the effects of melatonin on head and neck squamous cell carcinoma (HNSCC) cell lines (Cal-27 and SCC-9), which were treated with 0.1, 0.5, 1, and 1.5 mM melatonin combined with 8 Gy irradiation or 10 μM cisplatin. Clonogenic and MTT assays, as well as autophagy and apoptosis, involving flow cytometry and western blot, were performed in order to determine the cytotoxic effects of the treatments. Mitochondrial function was evaluated by measuring mitochondrial respiration, mtDNA content (RT-PCR), and mitochondrial mass (NAO). ROS production, antioxidant enzyme activity, and GSH/GSSG levels were analyzed using a fluorometric method. We show that high concentrations of melatonin potentiate the cytotoxic effects of radiotherapy and CDDP in HNSCC, which are associated with increased mitochondrial function in these cells. In HNSCC, melatonin induces intracellular ROS, whose accumulation plays an upstream role in mitochondria-mediated apoptosis and autophagy. Our findings indicate that melatonin, at high concentrations, combined with cisplatin and radiotherapy to improve its effectiveness, is a potential adjuvant agent.